Detect the virus before lesions form, not after changes appear
Em Rio Grande, a saúde pública dá um passo silencioso mas significativo: o exame que por décadas identificava danos já instalados cede lugar a uma tecnologia capaz de reconhecer o risco antes que ele se manifeste. A substituição gradual do Papanicolau pelo teste de DNA-HPV, prevista para alcançar todas as unidades básicas até o fim de 2026, reflete uma mudança de filosofia — da reação à prevenção — na proteção da saúde das mulheres.
- O câncer de colo do útero ainda mata mulheres que poderiam ter sido salvas por um diagnóstico mais precoce, e essa urgência impulsiona a mudança de protocolo.
- A transição exige reconfigurar décadas de rotina clínica: amostras que antes iam para lâminas de vidro agora seguem em meio líquido para análise por PCR em laboratório.
- Trinta e cinco profissionais de saúde de Rio Grande concluíram o primeiro ciclo de capacitação em 12 de maio, mas novas rodadas de treinamento nas próprias unidades ainda estão por vir.
- Com resultados negativos, o intervalo entre exames passa de frequente para quinquenal, aliviando a sobrecarga do sistema sem abrir mão da vigilância.
- A implementação completa em todas as unidades básicas de saúde está prevista para o final de 2026, enquanto a rede laboratorial estadual é coordenada para dar conta do novo fluxo.
As clínicas de saúde pública de Rio Grande estão se preparando para substituir gradualmente o Papanicolau por um método mais sensível de rastreamento do câncer de colo do útero. O teste de DNA-HPV detecta 14 tipos de papilomavírus humano de alto risco antes que qualquer lesão se forme, oferecendo uma janela de intervenção que o exame tradicional — capaz apenas de identificar alterações celulares já em curso — não consegue abrir. O público-alvo são mulheres e pessoas com útero entre 25 e 64 anos.
Para quem faz o exame, a coleta continua praticamente igual. A diferença está no destino da amostra: em vez de ser fixada em uma lâmina, as células são preservadas em meio líquido e enviadas a laboratório para análise por PCR, tecnologia que identifica o material genético do próprio vírus. Além da maior precisão, o novo protocolo estende o intervalo de rastreamento para cinco anos em casos com resultado negativo, reduzindo visitas desnecessárias sem comprometer a proteção.
O Brasil já vinha adotando o DNA-HPV em seu sistema público de saúde entre 2025 e 2026, com metodologia desenvolvida pela Fundação Oswaldo Cruz. Rio Grande se integra agora a esse movimento nacional. Em 12 de maio, 35 profissionais municipais — incluindo coordenadores técnicos, enfermeiros de unidades de saúde da família e equipes do programa de saúde da mulher — concluíram a primeira capacitação. Novos treinamentos presenciais nas unidades estão previstos para garantir que todo o fluxo, da coleta à entrega de resultados, funcione sem interrupções.
A meta é ter o teste disponível em todas as unidades básicas de saúde até o fim de 2026. Até lá, o município segue articulando a rede laboratorial estadual para processar as amostras. Para as mulheres de Rio Grande, a mudança representa uma aposta concreta na detecção precoce — e, com ela, na possibilidade real de melhores desfechos de saúde.
Rio Grande's public health clinics are preparing to introduce a more sensitive screening method for cervical cancer over the coming months. The new test, based on DNA-HPV detection, will gradually replace the Papanicolau exam that has been the standard in Brazil's unified health system for decades.
The shift represents a meaningful change in how the city approaches cancer prevention. Where the traditional Pap smear identifies cellular changes that have already begun, the DNA-HPV test can detect 14 types of high-risk human papillomavirus before any lesions form on the cervix. This earlier warning system gives doctors and patients more time to intervene, potentially preventing cancer from developing in the first place. The test will be offered to women and people with a uterus between ages 25 and 64.
The practical mechanics of the screening will feel familiar to patients. The sample collection process remains essentially the same as a Pap smear. But what happens to that sample afterward changes entirely. Instead of being smeared onto a glass slide, the cells will be placed in a liquid preservative and sent to a laboratory for analysis using PCR technology—a method that can identify the actual genetic material of the virus itself. This laboratory-based approach is more precise and allows for better detection of the virus before it causes visible damage.
Another significant change involves timing. If a woman's DNA-HPV test comes back negative, she will only need to repeat the screening once every five years, rather than the more frequent intervals required with traditional methods. This reduces unnecessary clinic visits while maintaining protective surveillance.
The technology is not new to Brazil. The Health Ministry began rolling out DNA-HPV testing across the national health system between 2025 and 2026, using a screening method developed domestically by the Oswaldo Cruz Foundation. Rio Grande is now joining this broader shift.
On Tuesday, May 12th, the city took a concrete step toward implementation. Thirty-five health professionals from Rio Grande's municipal system completed training on the new method. The group included technical coordinators, nurses from family health units, and staff overseeing the city's women's health program. Adriane Goularte Pinto, who oversees primary care services for the region, described the training as the beginning of an important effort to strengthen women's health services. She noted that additional training sessions will follow, including on-site instruction at individual clinics to ensure smooth workflows—from sample collection through laboratory submission to result delivery.
The full transition will take time. The city aims to have DNA-HPV testing available at all basic health units by the end of 2026. Until then, the health system will continue coordinating with the state laboratory network to process samples and return results. For women in Rio Grande seeking cervical cancer screening, the change represents a shift toward earlier detection and, potentially, better health outcomes.
Citas Notables
We are beginning an important process of improving health care for women and people with a uterus in Rio Grande— Adriane Goularte Pinto, superintendent of primary care services
La Conversación del Hearth Otra perspectiva de la historia
Why does detecting the virus before lesions form matter so much? Isn't a Pap smear already catching cancer early?
A Pap smear shows you what's already changed. The DNA-HPV test shows you who's at risk before anything changes. That's the difference between treating a problem and preventing it.
So this is about moving upstream in the disease process.
Exactly. If you know someone has a high-risk virus, you can monitor them closely, maybe intervene with treatment that stops the virus before it causes damage. The Pap smear is reactive. This is proactive.
The five-year interval for negative results—does that mean fewer clinic visits, or fewer chances to catch something?
Fewer visits, but not fewer chances. The test is so sensitive that if it's negative, your risk is genuinely low. You don't need to come back in a year. Five years is safe and reasonable.
What about the people who have to learn this new system? Thirty-five people trained on one Tuesday afternoon seems like a small number.
It is. That's why they're planning more training sessions at individual clinics. The real work happens when nurses and coordinators practice the new workflow in their own spaces, learning how to collect samples differently, how to send them to the lab, how to handle results.
By the end of 2026—that's still months away. What happens to women getting screened now?
They'll continue with the Pap smear until their clinic transitions. The shift is gradual. It's not like flipping a switch.